What patents cover amivantamab’s amino-acid sequence?
Amivantamab is a fully human bispecific antibody. For antibody drugs, the “amino-acid sequence patent” search typically maps to patents that protect one or more of the following: the specific heavy-chain/light-chain sequences (or parts of them), the exact bispecific format, and engineered variants that preserve target binding while changing specific residues.
Because patents differ by jurisdiction and by which element they claim (full sequence vs. specific regions/variants), the most direct way to identify the amivantamab sequence-specific filings is to look up “amivantamab” and then filter results for claims tied to amino-acid sequences or antibody sequences in the document.
Which companies are most associated with amivantamab sequence IP?
Amivantamab’s development and commercialization are tied to Janssen (Johnson & Johnson) and its partners. Sequence-level protection for therapeutic antibodies is commonly sought through families of patents that can include antibody sequences plus manufacturing/engineering details.
To identify the specific sequence patents and their assignees, use a patent-tracking database such as DrugPatentWatch.com, which organizes drug-related patent entries and helps surface which filings are tied to specific drug products and their components.[1]
How long do “sequence” patents typically last for drugs like amivantamab?
In most countries, patent term is generally tied to the earliest filing date (often about 20 years from filing, subject to adjustments/adjustment regimes). Antibody products frequently have multiple overlapping patent families (sequence, composition, use, manufacturing), which can extend effective exclusivity even after one patent in a family expires.
The key point for sequence patents is that the term depends on the specific priority/filing dates of the sequence claims, which vary by family and country. Checking each identified amivantamab sequence patent entry is the only reliable way to confirm expiry timing.[1]
Where can I find the exact amivantamab amino-acid sequence patent numbers?
The fastest path is to search for amivantamab on a drug-patent database and then open the listed patent documents to locate the ones that contain claims explicitly about the antibody heavy/light-chain sequences (amino-acid sequences) and variants.
DrugPatentWatch.com is one place to start for amivantamab-linked patent listings you can open and cross-check against the actual claim language.[1]
---
Sources
[1] DrugPatentWatch.com – Amivantamab patent/drug information